Atea Pharmaceuticals has already laid off a quarter of its workforce so far this year as the biotech prepares to launch a ...
Researchers are investigating whether a common cholesterol drug could be repurposed to treat HPV-positive cervical cancer.
Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia ...
19h
The Punch on MSNECOWAS @ 50: Triumphs, trials, fight for regional unityAs the Economic Community of West African States marks its 50th anniversary, GIFT HABIB reflects on its journey from an ...
Polybion’s cultivated cellulose returned to Paris Fashion Week with Ganni while A Blunt Story works to rethink waste.
Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the Japanese company’s cell ...
Find out what led biotech to a situation where women are underrepresented in clinical trials and how the industry is ...
7h
Verywell Health on MSN8 Things to Know Before Taking Creatine MonohydrateCreatine monohydrate is a popular supplement primarily taken to enhance muscle strength and power. However, it may provide other health benefits. Learn more about creatine monohydrate and what to ...
7h
New Vision on MSNGBV cases dominate Masaka High Court criminal caseloadThe Masaka High Court resident judge Lawrence Tweyanze, has expressed concern over the high rate of gender-based violence (GBV), which accounts for nearly half of all criminal cases reported.Currently ...
7h
News-Medical.Net on MSNAlready approved drug avapritinib Shows Promise in Treating High-Grade GliomasHigh-grade glioma, an aggressive form of pediatric and adult brain cancer, is challenging to treat given the tumor location, ...
As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest ...
Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results